里昂发表报指，复星医药(02196.HK) 2024年第四季和2025年第一季业绩面临显著压力，主要原因是医药板块疲软。该行认为，虽然盈利尚未出现明确的转势迹象，但预期近期的政策利好将为复苏铺路。该行调低复星医药2025和2026年收入预测各11.6%及15.1%，下调纯利预测各8.9%及16%，并将H股目标价由15.8元调低至15.6元，维持“跑赢大市”评级。(ha/da)(港股报价延迟最少...
Source Link里昂发表报指，复星医药(02196.HK) 2024年第四季和2025年第一季业绩面临显著压力，主要原因是医药板块疲软。该行认为，虽然盈利尚未出现明确的转势迹象，但预期近期的政策利好将为复苏铺路。该行调低复星医药2025和2026年收入预测各11.6%及15.1%，下调纯利预测各8.9%及16%，并将H股目标价由15.8元调低至15.6元，维持“跑赢大市”评级。(ha/da)(港股报价延迟最少...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.